ALNOV:EPA
Novacyt SA
€0.36
arrow_downward
-1.92%(-0.0070) 1 دن
28 اپریل, 2:53:10 PM GMT +2 · EUR
search
تمام علامات
1 دن
5 دن
1 ماہ
6 ماہ
YTD
1 سال
5 سال
زیادہ سے زیادہ
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_autoALNOV کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
کھولیں
€0.36
اعلی
€0.36
کم
€0.36
مارکیٹ کی سرمایہ کاری
۲٫۶۳ کروڑ
اوسط والیوم
۱٫۱۳ لاکھ
والیوم
۷۴٫۰۰ ہزار
52 ہفتے میں اعلی
€0.74
52 ہفتے کا کم
€0.36
EPS
-€0.50
بقایہ شیئرز
۷٫۲۶ کروڑ
ملازمین کی تعداد
۲۳۴
خبریں اور کہانیاں
ویب پر موجود ذرائع سے
24/7 Wall St.
·
8 منٹ پہلے
OpenAI’s Revenue Miss Is Ripples Through S&P 500 While Earnings Pour In
Stock Titan
·
17 منٹ پہلے
Credit Acceptance (NASDAQ: CACC) 2026 proxy outlines 10-year CEO RSU plan
Seeking Alpha
·
29 منٹ پہلے
4 Mutual Funds Retirees May Be Missing That Have Outperformed the S&P 500 (NYSEARCA:SPY)
پروفائل
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Novacyt SA کے بارے میں
AI مواد میں غلطیاں شامل ہو سکتی ہیں۔ مزید جانیں